Skip to search formSkip to main contentSkip to account menu

nebicapone

Known as: 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
&NA;Catechol-O-methyltransferase (COMT) inhibitors are drugs commonly used in the management of patients with Parkinson disease… 
2011
2011
Objectives  Patients with Parkinson's disease can benefit from controlled released levodopa dosage forms since there is a clear… 
Review
2010
Review
2010
  • K. Haasio
  • International review of neurobiology
  • 2010
  • Corpus ID: 21860089
2010
2010
To determine the efficacy, safety and tolerability of nebicapone, a new catechol‐O‐methyltransferase inhibitor for the treatment… 
2008
2008
Objective: To investigate the effects of nebicapone, a new catechol-O-methyltransferase (COMT) inhibitor, on levodopa… 
Review
2007
Review
2007
Parkinson's disease (PD) is a neurological disorder characterized by the degeneration of dopaminergic neurons, with consequent… 
2006
2006
Nebicapone (BIA 3-202; 1-[3,4-dihydroxy-5-nitrophenyl]-2-phenylethanone), a novel catechol-O-methyltransferase inhibitor, is… 
2002
2002
BIA 3-202, 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone 3, is a novel, reversible, and tight-binding peripheral inhibitor of…